Thinly traded nano cap Cesca Therapeutics (KOOL) has been trading up astoundingly on healthy volume since its bottom a few months back. No particular news accounts for its most recent breakneck move, although such moves of this kind sometimes occur before a public offering of equity. A few days ago, the company filed an updated S-3 for a $30M mixed shelf offering. In May, shares jumped on the announcement of positive data from a pilot study of its Acute Myocardial Infarction Rapid Stem Cell Therapy ((AMIRST)).
Cesca Therapeutics Inc. is focused on the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation processing and preservation of cell and tissue therapy products. It focuses in three target markets to serve patients physicians and partners: cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking. Cesca focuses on three areas: critical limb ischemia (CLI), acute myocardial infarction (AMI) and bone marrow transplant (BMT). The company offers SurgWerks and VXP System Platform, and CellWerks Platform. Its products include AutoXpress (AXP) System, MarrowXpress (MXP) System, BioArchive System and Res-Q 60 BMC. Cesca also provides cell manufacturing and banking services.
KOOL stock is in the process of a multi-year gap fill dating back to 2008. Interesting tape action on the stock as of late.
Drug Stock News 